Quantcast
Home > Quotes > MYOV

Myovant Sciences Ltd. Common Shares (MYOV) Quote & Summary Data

MYOV 
$23.67
*  
0.62
2.55%
Get MYOV Alerts
*Delayed - data as of Mar. 21, 2019  -  Find a broker to begin trading MYOV now
Exchange:NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
33.5
Today's High / Low
$ 24.955 / $ 23.05
Share Volume
284,874
90 Day Avg. Daily Volume
71,488
Previous Close
$ 24.29
52 Week High / Low
$ 27.45 / $ 14.32
Market Cap
1,676,132,845
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.82
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.49

Intraday Chart

Shares Traded

Share Volume:
284,874
90 Day Avg. Daily Volume:
71,488

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.82

Trading Range

The current last sale of $23.67 is 65.29% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 24.955 $ 27.45
 Low: $ 23.05 $ 14.32

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment women's health and endocrine diseases. Our goal is to be the leading global biopharmaceutical company focused on treating women's health and endocrine diseases in areas of high unmet medical need. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist. We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. In addition, we are developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. Both relugolix and MVT-602 were licensed to us by Takeda Pharmaceuticals International AG, or Takeda.  ... More ...  



Risk Grade

Where does MYOV fit in the risk graph?


Risk Grade Scale



Consensus Recommendation

Analyst Info